Our 2023 Integrated Annual Report is live!
A year of innovation and impact
In 2023, we entered the next phase of our journey of growth and innovation, reinforcing our position as a leading mid-sized biopharmaceutical company. With a sharp focus on our three therapy areas of Oncology, Rare Diseases, and Neuroscience, we achieved total sales of €3.128bn. These results demonstrate that our strategy is delivering, as we move away from reliance on a single blockbuster to further developing our four robust growth platforms.
2023 marked the beginning of a new phase of growth. With four potential launches in 2024, we are focused on excellence, execution and rapidity. Our progress to date demonstrates that our strategy is delivering, leading to a stronger, more resilient Ipsen.
The acquisition of Albireo and the integration of over 25 new programs into our pipeline since 2020 will enable us to continue to deliver groundbreaking therapies to patients worldwide in the coming years.
Beyond financial achievements, we demonstrated a profound commitment to sustainability through our Generation Ipsen strategy. We achieved a 36% reduction in Scope 1 and 2 emissions and a 29% reduction in Scope 3 emissions, and set ambitious goals to become carbon neutral by 2025 and reach net-zero emissions by 2045.
Our journey in 2023 is a story of transformation, innovation, and unwavering dedication as we Focus. Together. For patients and society.
Discover more about our journey and innovations.
Q1 2024 sales update
Applications now open for the 2024 Golden Ticket competition
FY 2023 results announcement
Ipsen sponsors 5 elite athletes on their journeys to the 2024 Paralympics
Examining the European Pharma legislation: EFPIA publishes the Dolon Report
Capital Markets Day 2023
2023 year to date and third-quarter sales results
Winner of Ipsen’s golden ticket announced as newest resident of Biolabs Hôtel Dieu
David Loew, Philippe Lopes Fernandes inaugurate Biolabs – Hôtel Dieu
